All News

Data from the phase 3 BREAKWATER trial supported full FDA approval of the encorafenib combination for metastatic CRC with a BRAF V600E mutation, demonstrating significant survival gains.

Patients with ocular myasthenia gravis (MG) should be regularly assessed to reduce the chances of progression to generalized MG.

Bruton tyrosine kinase–based therapies show promising but variable efficacy in Richter transformation, current data suggest.

The approval, dupilumab's ninth in the US, is supported by the phase 3 LIBERTY-AFRS-AIMS trial.

Doxy-PEP reshapes STI prevention, while congenital syphilis surges; experts urge scaling HIV and STI care infrastructure to improve testing and treatment access.

New research shows that adherence to antiretroviral therapy and pre-exposure prophylaxis depends on a steady budget through PEPFAR and SNAP.

The increase in CRC-related mortality in younger adults is driven by screening delays and advanced-stage diagnoses, according to Jordan Karlitz, MD.

The authors discuss ways to ensure that accountable care organizations do not bear the cost of inaccurate spending growth predictions.

FDA draft guidance outlines a new pathway to speed up approval of individualized genome and RNA therapies for rare diseases when RCTs are not feasible.

The first full day of CROI 2026 featured a lecture that outlined the next steps in treating and preventing HIV.

Digital health record integration boosts medication safety, as OTC use rivals prescription use in chronic care management, found a new study led by Jody L. Green, PhD, Uprise Health.

FDA approves 4-dose KwikPen for tirzepatide (Zepbound; Eli Lilly), offering a full month of weight management treatment in 1 device.

New GLP-1 pills challenge injections as competition, and discussions of possible Medicare coverage could push prices down.

Safety profiles, efficacy, and lifestyle factors inform shared decision-making and help optimize biologic selection in inflammatory disease management.

SGLT2 inhibitors were associated with significantly lower risks of kidney failure, cardiovascular events, mortality, and hepatic decompensation.

A new study finds higher radiation to key brain stem cell regions in NSCLC brain metastases tied to shorter survival.

Real-world data show vitiligo combination therapy with narrowband UVB or Janus kinase inhibitors drives steeper VASI improvement than monotherapy.

Many eligible patients miss lung cancer screening due to low awareness and systemic barriers, putting underserved groups at higher risk for late-stage disease.

Two analyses revealed significant delays and systemic barriers in the MS diagnostic journey alongside substantial clinical and economic burden in primary progressive MS.

Incorporating triglyceride-glucose-body mass index can help better account for metabolic impacts in patients with hypertension and heart failure with mildly reduced ejection fraction.

Julie Rosenthal, MD, MS, discusses signs and symptoms of age-related macular degeneration as well as methods of treatment.

Phase 2 trial finds 5-day preoperative RT in high-risk STS shows comparable wound complication rates and acceptable toxicity.

CROI 2026 highlights will include HIV prevention, long-acting treatments, and other advancements shaping research, clinical practice, and global policy.

From clinic closures to gene therapy costs, new data reveal how policy, prices, and structural racism reshape US health access and outcomes.

Reform priorities aim to reshape PBM oversight, delink compensation from drug prices, boost transparency, and protect pharmacy access.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The FDA approved acalabrutinib and venetoclax, a fixed‑duration all‑oral CLL/SLL first‑line combo, based on phase 3 AMPLIFY trial data.

The conference, held in Denver, Colorado, promises presentations on breaking research and the future of prevention.